Cargando…
Corona-Impfstoffe im Überfluss — was dann?
A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” i...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052199/ https://www.ncbi.nlm.nih.gov/pubmed/33897057 http://dx.doi.org/10.1007/s10273-021-2895-4 |
_version_ | 1783679879459373056 |
---|---|
author | Cassel, Dieter Ulrich, Volker |
author_facet | Cassel, Dieter Ulrich, Volker |
author_sort | Cassel, Dieter |
collection | PubMed |
description | A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” in the vaccination campaign is largely due to the limited supply of vaccines. Since J&J’s vaccine has recently been approved by the EU and additional production facilities are available, it is foreseeable that the capacities of the vaccination centres will no longer be sufficient. Moreover, at some point the existing unwillingness to vaccinate could become the final bottleneck in reaching herd immunity. This paper provides some calculations for these relationships. Against this background, it is questionable how well-prepared the present system is to cope with these foreseeable problems. |
format | Online Article Text |
id | pubmed-8052199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80521992021-04-19 Corona-Impfstoffe im Überfluss — was dann? Cassel, Dieter Ulrich, Volker Wirtschaftsdienst Analysen und Berichte A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” in the vaccination campaign is largely due to the limited supply of vaccines. Since J&J’s vaccine has recently been approved by the EU and additional production facilities are available, it is foreseeable that the capacities of the vaccination centres will no longer be sufficient. Moreover, at some point the existing unwillingness to vaccinate could become the final bottleneck in reaching herd immunity. This paper provides some calculations for these relationships. Against this background, it is questionable how well-prepared the present system is to cope with these foreseeable problems. Springer Berlin Heidelberg 2021-04-17 2021 /pmc/articles/PMC8052199/ /pubmed/33897057 http://dx.doi.org/10.1007/s10273-021-2895-4 Text en © Der/die Autor:in(nen) 2021 https://creativecommons.org/licenses/by/4.0/Open Access: Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht (https://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) ). Open Access wird durch die ZBW — Leibniz-Informationszentrum Wirtschaft gefördert. |
spellingShingle | Analysen und Berichte Cassel, Dieter Ulrich, Volker Corona-Impfstoffe im Überfluss — was dann? |
title | Corona-Impfstoffe im Überfluss — was dann? |
title_full | Corona-Impfstoffe im Überfluss — was dann? |
title_fullStr | Corona-Impfstoffe im Überfluss — was dann? |
title_full_unstemmed | Corona-Impfstoffe im Überfluss — was dann? |
title_short | Corona-Impfstoffe im Überfluss — was dann? |
title_sort | corona-impfstoffe im überfluss — was dann? |
topic | Analysen und Berichte |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052199/ https://www.ncbi.nlm.nih.gov/pubmed/33897057 http://dx.doi.org/10.1007/s10273-021-2895-4 |
work_keys_str_mv | AT casseldieter coronaimpfstoffeimuberflusswasdann AT ulrichvolker coronaimpfstoffeimuberflusswasdann |